Symbiotec Pharmalab Limited IPO
24 Aug 2026 – 27 Aug 2026
Share Price
- Candle
- 6 Oct
- O
- ₹1,168.9
- H
- ₹1,209.5
- L
- ₹1,138.6
- C
- ₹1,149.5
24 trading days since listing · NSE end-of-day prices
Issue Details
- Price Band
- ₹938 – ₹988
- Lot Size
- 15 shares
- Min Investment
- ₹14,820 (1 lot · 15 shares)
- Face Value
- ₹2
- Issue Size
- Initial Public Offer of Fresh Issue of Aggregating Up to Rs. 1,500 million and Offer for sale up to Rs. 16,070 million (Including Eligible Employees Reservation Portion of Aggregating up to Rs. 30 million and Anchor portion of 53,25,909 Equity shares)
- Registrar
- MUFG Intime India Private Limited ↗
Timetable
GMP History
Latest GMP ₹185 · Last updated 7 Oct 2026, 11:51 am IST
| Date | GMP | GMP % | Change | Est. Listing | Updated (IST) |
|---|---|---|---|---|---|
| 31 Aug | ₹200 | +20.2% | −₹40 | ₹1,188 | |
| 30 Aug | ₹240 | +24.3% | — | ₹1,228 | |
| 29 Aug | ₹240 | +24.3% | −₹20 | ₹1,228 | |
| 28 Aug | ₹260 | +26.3% | −₹10 | ₹1,248 | |
| 27 Aug | ₹270 | +27.3% | −₹45 | ₹1,258 | |
| 26 Aug | ₹315 | +31.9% | −₹37 | ₹1,303 | |
| 25 Aug | ₹352 | +35.6% | −₹36 | ₹1,340 | |
| 24 Aug | ₹388 | +39.3% | +₹8 | ₹1,376 | |
| 23 Aug | ₹380 | +38.5% | — | ₹1,368 | |
| 22 Aug | ₹380 | +38.5% | — | ₹1,368 |
Subscription
Day-wise subscription
| Date | QIB | NII / HNI | Retail | Total |
|---|---|---|---|---|
| 27 Aug | 172.03x | 73.63x | 12.96x | 71.26x |
| 26 Aug | 0.59x | 12.18x | 5.05x | 5.30x |
| 25 Aug | 0.54x | 2.99x | 2.10x | 1.85x |
| 24 Aug | 0.35x | 1.04x | 0.95x | 0.80x |
Financials
All values in ₹ crore
About Symbiotec Pharmalab
Incorporated in 2002, Symbiotec Pharmalab Ltd. is a pharmaceutical and biotechnology company engaged in the development and manufacturing of active pharmaceutical ingredients, nutritional ingredients, and specialty products. The company caters to domestic and international markets across regulated and emerging regions. It emphasizes research-driven manufacturing, quality compliance, and sustainable processes. Symbiotec Pharmalab Ltd. supports pharmaceutical, nutraceutical, and wellness industries by delivering high-quality, innovative ingredients aligned with global standards. With over 30 years of industry experience, they have evolved from a lab-scale steroidal-hormone API manufacturer in 1995 into an industrial-scale, backward-integrated platform with approvals from the United States Food and Drug Administration (“US FDA”), European Union Good Manufacturing Practices (“EU-GMP”), Ministry of Food and Drug Safety, Korea and other global organisations. As of June 30, 2025, they had two operational industrial-scale API manufacturing facilities with a maximum chemical synthesis capacity of 584.67 metric tonnes (“MT”) and fermentation capacity of 300 kilolitres. Competitive Strengths: Global leadership in corticosteroid and steroidal-hormone APIs Long-standing relationships with domestic and global customer base Fully-invested, multi-scale, vertically integrated manufacturing platform with sustainable practices and clean regulatory track record. Continuous investment in R&D, with leading technological capabilities among Indian peers. Ability to leverage science and existing competencies to increase total addressable market and deepen intellectual property-driven offerings
As published in the company's own offer documents.
Strengths
- Global leadership in corticosteroid and steroidal-hormone APIs
- Long-standing relationships with domestic and global customer base
- Fully-invested, multi-scale, vertically integrated manufacturing platform with sustainable practices and clean regulatory track record.
- Continuous investment in R&D, with leading technological capabilities among Indian peers.
- Ability to leverage science and existing competencies to increase total addressable market and deepen intellectual property-driven offerings
As stated by the company in its prospectus — not our assessment.
The company's own risk factors are not shown here. They run to dozens of pages in the Red Herring Prospectus, under “Risk Factors”, and are worth the read before applying.
Lead Managers
- JM Financial Limited
- Avendus Capital Private Limited
- Motilal Oswal Investment Advisors Limited
- Nomura Financial Advisory
- Securities (India) Private Limited
Offer details
Application sizes
| Category | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min)one lot, the smallest bid allowed | 1 | 15 | ₹14,820 |
| Retail (max)most that stays under ₹2L | 13 | 195 | ₹1,92,660 |
| S-HNI (min)first bid over ₹2L | 14 | 210 | ₹2,07,480 |
| S-HNI (max)most that stays under ₹10L | 67 | 1,005 | ₹9,92,940 |
| B-HNI (min)first bid over ₹10L | 68 | 1,020 | ₹10,07,760 |
Priced at the top of the band, which is what a cut-off bid pays. Retail ends at ₹2,00,000 and S-HNI at ₹10,00,000; these are SEBI's limits, not the issuer's.
Issue mechanics
- Issue Type
- Book Building
- Discount
- Rs. 90 per equity share to Eligible Employees
- Categories
- FI, IC, MF, FII, OTH, CO, IND, NOH and EMP
- Max Bid (Retail)
- Rs. 2,00,000
- Max Bid (Employee)
- Rs. 5,00,000
- Tick Size
- Re. 1
- Bidding Hours
- 10.00 a.m. to 5.00 p.m.
- UPI Mandate Cut-off
- 27-Aug-2026 (upto 5:00 PM) The new cut-off time for UPI mandate acceptance is 05:00 PM on last day of IPO bidding. Further bids with confirmed status of mandate amount blocked (RC100) shall be considered as valid applications and hence, investors are advised to submit their UPI applications in IPO well in advance to avoid any last minute technical/systemic constraints that may hamper their ability
- Sponsor Bank
- Axis Bank Limited and Kotak Mahindra Bank Limited
Registrar
- Name
- MUFG Intime India Private Limited
- Address
- C-101, Embassy 247, L.B.S. Marg, Vikhroli (West), Mumbai 400 083, Maharashtra, India
- Contact
- Shanti Gopalkrishnan, +91 810 811 4949 , symbiotecpharmalab.ipo@in.mpms.mufg.com
Documents
- Red Herring ProspectusThe full offer documentPDF
- Basis of Issue PriceHow the band was arrived atPDF
- Anchor AllocationWho was allotted before the issue openedPDF
Published by NSE as ZIP archives; opened here as the PDF inside.
Collected from NSE and public sources. Always confirm against the prospectus before applying.
Frequently Asked Questions
What is the GMP of Symbiotec Pharmalab Limited IPO today?
The latest grey market premium for Symbiotec Pharmalab Limited IPO is ₹185. GMP is unofficial and indicative only — it is not a guarantee of listing price.
What is the price band of Symbiotec Pharmalab Limited IPO?
The price band is ₹938 – ₹988, with a lot size of 15 shares. The minimum investment is ₹14,820.
When does Symbiotec Pharmalab Limited IPO open and close?
The issue opens on 24 Aug 2026 and closes on 27 Aug 2026. Listing is expected on 1 Sept 2026.
Who is the registrar for Symbiotec Pharmalab Limited IPO?
MUFG Intime India Private Limited is the registrar. Allotment status can be checked on the registrar's website once allotment is finalised.